
IMHOTEP, PJP, and more
May 14, 2026 - 00:09:59
Radio and PodcastLive Radio & Podcasts
The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implications for clinical practice. Check out th...
Vepdegestrant is an episode from OncoPharm by OncoPharmPod. The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implicat...
This episode belongs to OncoPharm.
Use the player on this page to stream the episode online.
Published May 7, 2026, 00:11:35 long, audio available.
The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implications for clinical practice. Check out the Oncology Insights Newsletter:
You can listen to Vepdegestrant online on Radio and Podcast. Open the player on this page to stream the available audio.
Vepdegestrant is an episode from OncoPharm by OncoPharmPod.
This episode is 00:11:35 long.
This episode was published on May 7, 2026.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from OncoPharm when more episodes are available from the podcast feed.